CRICKi012-A

iFCI017

General

Cell Line

hPSCreg name CRICKi012-A
Cite as:
CRICKi012-A (RRID:CVCL_C5T4)
Alternative name(s)
iFCI017
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
LCPHi001-A
Donor's gene variants:
GBA
Donor diseases:
obsolete_Parkinson's disease
DANi004-A
(PRKN-004-C1)
Donor's gene variants:
PRKN
Donor diseases:
Parkinson Disease
DANi006-F
(GBA-006-C6)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
DANi011-A
(LRRK2-011-C1)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson Disease
LCSBi009-A
(RHOT1_R272Q_clone1_PD)
Donor diseases:
Parkinson Disease
LCSBi010-A
(RHOT1_R450C_clone5_PD)
Donor diseases:
Parkinson Disease
ZZUi024-A
(ZZU-iPS-AD-APP-002)
Donor diseases:
Alzheimer's Disease
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
INNDSUi008-A
(JKL-SCA)
Donor diseases:
Machado-Joseph disease
ZZUi037-A
(ZZU-iPS-SCA3-004)
Donor diseases:
Spinocerebellar Ataxia Type 3
CSBZZUi001-A
(CSBZZU_PS1_001)
Donor diseases:
Alzheimer disease
LUMCi008-A
(152-2, LUMC0152iHD02)
Donor diseases:
Huntington disease
LUMCi008-B
(152-3, LUMC0152iHD03)
Donor diseases:
Huntington disease
LUMCi008-C
(152-4, LUMC0152iHD04)
Donor diseases:
Huntington disease
LUMCi022-A
(115-1, LUMC0115iATAX01)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-B
(115-2, LUMC0115iATAX02)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-C
(115-7, LUMC0115iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
OSRi014-A
(OSR_002#1)
Donor diseases:
Multiple Sclerosis
OSRi015-A
(OSR_003#56)
Donor diseases:
Multiple Sclerosis
NCSi001-A
(NCS065)
Donor diseases:
Alzheimer's Disease
OSRi017-A
(PTL6)
Donor diseases:
Friedreich Ataxia
NCSi007-A
(NCS071)
Donor's gene variants:
APOE
Donor diseases:
Alzheimer's Disease
SAPi002-A
(ALS I, ALS I–FUS-R514S/wt, FUS-R514S/wt)
Donor diseases:
amyotrophic lateral sclerosis
LCPHi003-A
Donor's gene variants:
LRP10
Donor diseases:
Parkinson Disease
LCSBi013-A
(GL2)
Donor diseases:
Parkinson Disease
UMi036-A
(ND34263)
Donor diseases:
Parkinson Disease
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
DANi002-C
(GBA-002-C3)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
ZZUi027-A
(ZZU-iPS-PD-RAB39b-002)
Donor diseases:
Parkinson Disease
DANi003-H
(GBA-003-C8)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
DANi005-A
(LRRK2-GBA-005-C1)
Donor's gene variants:
GBA, LRRK2
Donor diseases:
Parkinson Disease
LCSBi001-A
(VPS35 1_2)
Donor diseases:
obsolete_Parkinson's disease
DANi007-A
(PINK1-007-C1)
Donor's gene variants:
PINK1
Donor diseases:
Parkinson Disease
FDHSi002-A
(FDITBRi002-A)
Donor diseases:
Parkinson Disease
DANi008-F
(SNCA-008-C6)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson Disease
ESi119-A
(SPG FiPS1-Ep6F-4)
Donor's gene variants:
APAS1
Donor diseases:
Hereditary Spastic Paraplegia
Last update 2nd November 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator The Francis Crick Institute Limited (CRICK)
Owner The Francis Crick Institute Limited (CRICK)
Distributors
Derivation country United Kingdom

External Databases

BioSamples SAMEA112233748
Cellosaurus CVCL_C5T4
Wikidata Q116048795

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:

the cell line can be obtained by third parties using appropriate MTA

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation.
Synonyms
  • YOPD
  • Early-onset Parkinson disease

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

External Databases (Donor)

BioSamples SAMEA112233749

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? This project has been approved and monitored by [19/LO/1796] and collaborates with researchers from around the world.
Approval number 19/LO/1796
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms

Reprogramming method

Vector type None

Vector free reprogramming

Type of used vector free reprogramming factor(s)
mRNA
mRNA

Other

Selection criteria for clones MANUALLY PICKED (iPSC MORPHOLOGY)
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Method documentation
iFCI017 FLOW FINAL FIGURES.png
Flow cytometry showed markers for OCT4 and SSEA-4 were detected, while SSEA-1 was not detected.
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
KARYOSTAT
Karyotyping method: G-Banding

Other Genotyping (Cell Line)